174 related articles for article (PubMed ID: 3257274)
21. In vivo activation of LAK cells during systemic IL-2 therapy.
Lang P; Vitté-Mony I; Farace F; Stancou R; Triebel F; Escudier B; Hercend T; Bertoglio J
Eur Cytokine Netw; 1990; 1(3):185-8. PubMed ID: 2129800
[No Abstract] [Full Text] [Related]
22. Lymphokine-activated killer (LAK) activity against autologous malignant tumors of the skin.
Fukui Y; Iseki R; Ohashi M
J Invest Dermatol; 1988 Oct; 91(4):319-22. PubMed ID: 3262690
[TBL] [Abstract][Full Text] [Related]
23. Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes.
Lamers HJ; Gratama JW; van Putten WL; Stoter G; Bolhuis RL
Cancer Res; 1991 May; 51(9):2324-8. PubMed ID: 2015597
[TBL] [Abstract][Full Text] [Related]
24. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
[TBL] [Abstract][Full Text] [Related]
25. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH
Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457
[TBL] [Abstract][Full Text] [Related]
26. Induction of lymphokine-activated killer cytotoxicity with interleukin-2 and tumor necrosis factor-alpha against primary lung cancer targets.
Yang SC; Owen-Schaub L; Grimm EA; Roth JA
Cancer Immunol Immunother; 1989; 29(3):193-8. PubMed ID: 2543502
[TBL] [Abstract][Full Text] [Related]
27. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.
Belldegrun A; Tso CL; Kaboo R; Pang S; Pierce W; deKernion JB; Figlin R
J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):149-61. PubMed ID: 8732698
[TBL] [Abstract][Full Text] [Related]
28. In vitro activation of lymphocytes by interleukin 2 in patients with renal cell carcinoma.
Ziegelbaum MM; Finke JH; Tubbs R; Montie JE; Pontes JE; Lewis I
Urology; 1989 Feb; 33(2):106-9. PubMed ID: 2783793
[TBL] [Abstract][Full Text] [Related]
29. [Study on adoptive immunotherapy on patients with renal cell carcinoma. I. Functional characteristics of peripheral blood mononuclear cells and serum immunosuppressive factors in patients with renal cell carcinoma].
Usui A
Nihon Hinyokika Gakkai Zasshi; 1990 Jul; 81(7):1051-7. PubMed ID: 2214468
[TBL] [Abstract][Full Text] [Related]
30. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
31. Optimal methods for generating expanded lymphokine activated killer cells capable of reducing established murine tumors in vivo.
Lafreniere R; Rosenstein MS; Rosenberg SA
J Immunol Methods; 1986 Nov; 94(1-2):37-49. PubMed ID: 2878049
[TBL] [Abstract][Full Text] [Related]
32. Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results.
Tomita Y; Katagiri A; Saito K; Imai T; Saito T; Tanikawa T; Terunuma M; Nishiyama T; Takahashi K
Int J Urol; 1998 Jan; 5(1):16-21. PubMed ID: 9535595
[TBL] [Abstract][Full Text] [Related]
33. Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicity.
Kaufmann Y; Levanon M; Davidsohn J; Ramot B
J Immunol; 1987 Aug; 139(3):977-82. PubMed ID: 3496395
[TBL] [Abstract][Full Text] [Related]
34. Enhanced susceptibility of c-myc antisense oligonucleotide-treated human renal cell carcinoma cells to lysis by peripheral blood lymphocytes.
Mizutani Y; Bonavida B; Fukumoto M; Yoshida O
J Immunother Emphasis Tumor Immunol; 1995 Feb; 17(2):78-87. PubMed ID: 7647959
[TBL] [Abstract][Full Text] [Related]
35. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.
Melder RJ; Whiteside TL; Vujanovic NL; Hiserodt JC; Herberman RB
Cancer Res; 1988 Jun; 48(12):3461-9. PubMed ID: 3259468
[TBL] [Abstract][Full Text] [Related]
36. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
Hermann GG; Zeuthen J; Claësson MH
Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282
[TBL] [Abstract][Full Text] [Related]
37. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma.
Law TM; Motzer RJ; Mazumdar M; Sell KW; Walther PJ; O'Connell M; Khan A; Vlamis V; Vogelzang NJ; Bajorin DF
Cancer; 1995 Sep; 76(5):824-32. PubMed ID: 8625186
[TBL] [Abstract][Full Text] [Related]
38. Renal carcinoma cell lines inhibit natural killer activity via the CD94 receptor molecule.
Stanley AJ; Gough MJ; Banks RE; Selby PJ; Patel PM
Cancer Immunol Immunother; 2001 Jul; 50(5):260-8. PubMed ID: 11499809
[TBL] [Abstract][Full Text] [Related]
39. [Low susceptibility of choriocarcinoma cell lines to lymphokine activated killer (LAK) cells].
Kameda T; Negoro T; Hagiwara M; Koyama M; Matsuzaki N; Saji F; Tanizawa O
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jan; 41(1):1-6. PubMed ID: 2784473
[TBL] [Abstract][Full Text] [Related]
40. In vitro cytolysis of primitive neuroectodermal tumors of the posterior fossa (medulloblastoma) by lymphokine-activated killer cells.
George RE; Loudon WG; Moser RP; Bruner JM; Steck PA; Grimm EA
J Neurosurg; 1988 Sep; 69(3):403-9. PubMed ID: 3261328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
